Our Commitment to Patients
With Progesterone Receptor Positive (PR+) Cancers
At Context Therapeutics, we are passionate about improving health and committed to helping people with cancer. To fulfill our promise to patients, we have created the ONWARD Clinical Trial network to evaluate our investigational product, Apristor (onapristone xr), in PR+ breast, ovarian, and uterine (endometrial) cancers.
Phase 2 Trial in HR+ Breast Cancer
ONWARD 201 will evaluate fulvestrant alone and in combination with Apristor in second line (2L) metastatic breast cancer patients who are ER+,PR+,HER2- and who have failed first line Cdk4/6 inhibitor plus antiestrogen combination therapy,
Window of Opportunity in PR+ Breast Cancer
ONWARD 203 will evaluate Apristor in a pre-surgical, window of opportunity study in treatment naive PR+ breast cancer patients.
Phase 2 Basket Trial in PR+ Gynecologic Cancers
ONWARD 220 will evaluate Apristor in 2L/3L chemotherapy resistant uterine (endometrial) and ovarian (low grade serous, granulosa) cancer patients.
At Context Therapeutics, we are committed to the advancement of medical and scientific knowledge that addresses the unmet needs of patients with hormone driven cancers.
To learn more about our ISTs, click here.
Developing the next generation of antihormonal therapies to treat breast, prostate, and ovarian cancers.
Apristor is an investigational New Chemical Entity (NCE) for PR+ breast and ovarian cancers.